CD8A and neoplasm: Specifically, NPS treated mice do not show T cell reactivity to either the HPV16 E749-57 peptide nor the ampitope sequence, however depletion of CD8+ cells and subsequent loss of protection against tumor challenge indicate that NPS is inducing an immune response against the tumor driven by one or more neo-antigens that have yet to be identified.